{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:19:57Z","timestamp":1769602797761,"version":"3.49.0"},"reference-count":22,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To analyze the effectiveness of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a related HLA-identical donor in patients with multiple myeloma (MM).\r\nMaterials and methods. From 2013 to 2018, the study included 8 patients (6 men, 2 women) aged from 27 to 55 years (median 39 years) with MM who underwent allo-HSCT from a related HLA-identical donor (7 patients  after auto-HSCT, in 1 case  without previous auto-transplantation). All patients required 2 or more lines of induction therapy, while the achieved antitumor effect was unstable. Before allo-HSCT, complete and very good partial remission was determined in isolated cases, in 4 patients the response was regarded as partial remission, stabilization  in 1 observation, progression  in 1 patient. All patients underwent reduced intensity conditioning (fludarabine 30 mg\/m2  6 days + busulfan 4 mg\/kg  2 days). Immunosuppressive therapy included the administration of antithymocyte globulin and post-transplant cyclophosphamide.\r\nResults. Severe acute GVHD (grade 34) was observed in 3 (37.5%) cases, which resulted in death in 1 case. A stable antitumor response was achieved in 5 (62.5%) patients, complete remission lasts for 2986 months after allo-HSCT. Specific therapy for these patients is not carried out. The 7-year progression-free survival rate was 75%, the 7-year overall survival rate was 84%, with a median follow-up of 65 months. The transplant-related mortality was 12.5%.\r\nConclusion. Allo-HSCT is considered as an alternative method of therapy for young patients with aggressive MM. Allo-HSCT in MM in some cases leads to long-term immunological control of the tumor.<\/jats:p>","DOI":"10.26442\/00403660.2021.07.200929","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T09:51:35Z","timestamp":1627033895000},"page":"778-784","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma"],"prefix":"10.26442","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-171X","authenticated-orcid":false,"given":"Maiia V.","family":"Firsova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4966-8146","authenticated-orcid":false,"given":"Larisa P.","family":"Mendeleeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-3566","authenticated-orcid":false,"given":"Elena N.","family":"Parovichnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-6202","authenticated-orcid":false,"given":"Maksim V.","family":"Solovev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-6276","authenticated-orcid":false,"given":"Larisa A.","family":"Kuzmina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-1619","authenticated-orcid":false,"given":"Natalia V.","family":"Risinskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-4930","authenticated-orcid":false,"given":"Tatiana V.","family":"Abramova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-6066","authenticated-orcid":false,"given":"Irina V.","family":"Galtseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-5557","authenticated-orcid":false,"given":"Valerii G.","family":"Savchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4600"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.033"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1312"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88(7):2787-93","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036848"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7929"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70243-1"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339945"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168823"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-469452"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141598"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.173"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.101"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200881"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065464"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3869"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0264-8"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0516-2"},{"key":"ref22","unstructured":"\u041f\u0430\u0440\u043e\u0432\u0438\u0447\u043d\u0438\u043a\u043e\u0432\u0430 \u0415.\u041d., \u0412\u0430\u0441\u0438\u043b\u044c\u0435\u0432\u0430 \u0412.\u0410., \u0414\u043e\u0432\u044b\u0434\u0435\u043d\u043a\u043e \u041c.\u0412. \u0438 \u0434\u0440. \u041f\u0440\u043e\u0442\u043e\u043a\u043e\u043b\u044b \u0442\u0440\u0430\u043d\u0441\u043f\u043b\u0430\u043d\u0442\u0430\u0446\u0438\u0438 \u0430\u043b\u043b\u043e\u0433\u0435\u043d\u043d\u044b\u0445 \u0433\u0435\u043c\u043e\u043f\u043e\u044d\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u0441\u0442\u0432\u043e\u043b\u043e\u0432\u044b\u0445 \u043a\u043b\u0435\u0442\u043e\u043a. \u041c.. 2020; c. 218-24 [Parovichnikova EN, Vasileva VA, Dovydenko MV, et al. Allogeneic Hematopoietic Stem Cell Transplant Protocols. Moscow, 2020; p. 218-24 (in Russian)]"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/76313\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/76313\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T12:40:39Z","timestamp":1637325639000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/76313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2021.07.200929","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,23]]}}}